Our Services
Medical Information
Helpful Resources
Published on: 9/17/2026
Long-term Celebrex (celecoxib) use carries a modest but real risk of cardiovascular events such as heart attack, stroke, and high blood pressure, along with reduced kidney blood flow that can lead to fluid retention or declining kidney function, especially at higher doses, in older adults, or when combined with diuretics, ACE inhibitors, or ARBs. Your personal risk depends on several factors, including your dose, duration of use, existing heart or kidney disease, and other medications, so see below to understand the details that matter most before continuing or stopping treatment. Warning signs like swelling in the legs, sudden weight gain, chest pain, shortness of breath, or decreased urination deserve prompt medical attention, and periodic blood pressure and kidney function monitoring is generally recommended. Because these symptoms overlap with many other conditions, it helps to get a clear, organized picture of what you are experiencing before your next appointment. Take a free, instant, online symptom check to see which possible causes fit your situation and what steps to take next.
Last reviewed for medical accuracy: 09/17/2026
Celebrex (celecoxib) is a prescription nonsteroidal anti-inflammatory drug (NSAID) often used for arthritis, chronic pain and inflammation. While it can offer relief, taking it long term carries potential risks—especially for your heart and kidneys. This guide explains what to watch for, who’s at higher risk and how to balance benefits and risks.
Celecoxib selectively blocks the COX-2 enzyme, reducing inflammation and pain. However, COX-2 inhibition may also disrupt the balance between prostacyclin (a vessel-dilating, anti-clotting molecule) and thromboxane (a vessel-constricting, clot-promoting molecule). Over time, this imbalance can raise cardiovascular risks:
Key points from major studies and guidelines:
Prostaglandins also help maintain healthy blood flow in the kidneys. By inhibiting COX-1 and COX-2, Celebrex can interfere with kidney perfusion, leading to:
Who’s most vulnerable?
Regular monitoring of kidney function (e.g., serum creatinine, blood urea nitrogen) is essential if you’re on long-term celecoxib.
For many, the relief from joint pain and improved quality of life outweighs potential harms. Still, here’s how to minimize risks:
Ask your doctor if celecoxib remains the right choice if you have:
Your healthcare provider may recommend alternative treatments or closer monitoring.
Stay alert for symptoms that could signal serious heart or kidney issues:
Heart-related
Kidney-related
If you experience any of the above, don’t wait—consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. And be prepared to seek immediate medical care if symptoms are severe or sudden.
Long-term Celebrex therapy isn’t inherently unsafe, but it requires a tailored approach:
Even if you feel well now, routine check-ins can catch early changes before they become serious.
Celebrex can be an effective tool against chronic pain, but like all NSAIDs, it’s not risk-free. By:
you’ll be in the best position to protect your heart and kidneys.
If you ever feel concerned about new or worsening symptoms—chest pain, swelling, changes in urination or anything else that feels serious—speak to a doctor right away. Your provider can help you decide whether to continue Celebrex, switch therapies or add protective measures to your regimen.
(References)
* Cheung R, Lowry S. Celecoxib. J R Soc Med. 2006 Jul;99(7):336. doi: 10.1177/014107680609900714. PMID: 16816261; PMCID: PMC1484551.
* Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM, PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13. PMID: 27959716.
* Ozer EK, Goktas MT, Kilinc I, Bariskaner H, Ugurluoglu C, Iskit AB. Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats. Biomed Pharmacother. 2017 Feb;86:583-589. doi: 10.1016/j.biopha.2016.11.102. Epub 2016 Dec 23. PMID: 28024294.
* Reed GW, Nissen SE. NSAID choice: lessons from PRECISION. Aging (Albany NY). 2019 Apr 29;11(8):2181-2182. doi: 10.18632/aging.101930. PMID: 31035258; PMCID: PMC6520008.
* Cheng S, Xin M, Zhou J, Cheng Y, Xu G, Zhou Y, Li Z, Liang F. The cardiovascular risk of celecoxib for knee osteoarthritis: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020 May;99(18):e19976. doi: 10.1097/MD.0000000000019976. PMID: 32358371; PMCID: PMC7440337.
* Atashbar S, Jamali Z, Khezri S, Salimi A. Celecoxib decreases mitochondrial complex IV activity and induces oxidative stress in isolated rat heart mitochondria: An analysis for its cardiotoxic adverse effect. J Biochem Mol Toxicol. 2022 Jan;36(1):e22934. doi: 10.1002/jbt.22934. Epub 2021 Oct 19. PMID: 34668290.
* Obeid S, Libby P, Husni E, Wang Q, Wisniewski LM, Davey DA, Wolski KE, Xia F, Bao W, Walker C, Ruschitzka F, Nissen SE, Lüscher TF. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 3;8(6):611-621. doi: 10.1093/ehjcvp/pvac015. PMID: 35234840.
* Maruyama K, Tanaka S, Hiramoto K, Ooi K. Effect of Celecoxib Administration on the Skin of 40-Week-Old Mice. Biol Pharm Bull. 2022 Dec 1;45(12):1857-1861. doi: 10.1248/bpb.b22-00518. Epub 2022 Sep 27. PMID: 36171113.
* Sciscent BY, Hallan DR, Bhanja D, Staub J, Crossman D, Rizk EB, Zacko JC, Park H, Hazard SW. Early Celecoxib Use in Spontaneous Intracerebral Hemorrhage is Associated with Reduced Mortality. Neurocrit Care. 2024 Dec;41(3):788-797. doi: 10.1007/s12028-024-01996-2. Epub 2024 May 15. PMID: 38750392.
* Agarwal N, St John J, Sunder V, Sarraju A, Laffin LJ. Association of Systolic Blood Pressure Time in Target Range With Cardiovascular Events Among PRECISION Participants. J Clin Hypertens (Greenwich). 2025 Jul;27(7):e70009. doi: 10.1111/jch.70009. PMID: 40627752; PMCID: PMC12236988.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.